Company Overview and News


Add ARQL
to your dashboard

Headline News

ROTY Edition 1 Volume 54: Performance And Position Updates

2017-11-21 seekingalpha
Biotech sector performance in November has been ¨blah¨, but thankfully ROTY model account returns have been on the upswing. (40-1)

ROTY Edition 1 Volume 52: Material Updates And Trades

2017-11-15 seekingalpha
Performance of the ROTY model account has suffered lately due to both continued weakness in the biotech sector as well as a couple losers that we cut recently. (15-0)

Loxo Oncology: Several Catalysts In The Near To Medium Term

2017-11-13 seekingalpha
I've revisited this targeted oncology play a couple of times as the story continues to play out and management executes. (37-0)

Current Breakdown Of The ROTY Model Account

2017-11-12 seekingalpha
Every so often I like to break down our current holdings in the ROTY model account. (84-0)

ROTY Edition 1 Volume 49: Updates From Quarterly Calls And Trades

2017-11-10 seekingalpha
I remind readers of the need to review quarterly results, filings, and conference calls to monitor changes with their stock holdings. (113-0)

ArQule's (ARQL) CEO Paolo Pucci on Q3 2017 Results - Earnings Call Transcript

2017-11-09 seekingalpha
Good day, ladies and gentlemen and welcome to the ArQule Third Quarter 2017 Earnings Conference Call. At this time all participants are in a listen-only mode. Later there will be a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder this conference call is being recorded. (11-1)

Arqule: Updates After 3Q Results

2017-11-09 seekingalpha
Shares have climbed slightly since my initial article, where I overcame my bias against this ¨penny stock¨ and discovered what could be a promising 2018 story. (9-0)

ROTY Edition 1 Volume 48: Cutting A Position Loose And Promising Updates On Current Holdings

2017-11-08 seekingalpha
I remind readers the importance of constantly reevaluating current holdings in your brokerage accounts and questions to ask ourselves. (128-2)

ROTY Volume 1 Edition 46: Bouncing Back In November And Several New Trades

2017-11-06 seekingalpha
Data from the TiNivo study makes AVEO Pharmaceuticals more attractive to me on multiple time frames and I review the presentation with readers below. (310-7)

ArQule: Several Ways To Win Here

2017-11-02 seekingalpha
The FDA granted Rare Pediatric Disease Designation to drug candidate miransertib (ARQ 092) for the treatment of Proteus syndrome, and they could receive a priority review voucher if approved. (44-2)

ROTY Volume 1 Edition 45: More Trades And Updates

2017-11-02 seekingalpha
I finally cut a "loser" from the ROTY model account. While the fundamental thesis appears on track, I can`t ignore the weak technicals any longer. (68-1)

Your Daily Pharma Scoop: Teva Q3 Results, Boost For RedHill, Clovis Reports Rubraca Sales

2017-11-02 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (685-3)

ARQL / ArQule, Inc. - Institutional Ownership and Shareholders - Fintel.io

2017-10-16 fintel.io
ArQule, Inc. (NASDAQ:ARQL) has 44 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 43,974,909 shares. Largest shareholders include First Eagle Investment Management, LLC, Nantahala Capital Management, LLC, Bvf Inc/il, Vanguard Group Inc, and NEA Management Company, LLC. (9-1)

BRIEF-Arqule announces $15.7 mln private placement of common stock

2017-10-16 reuters
* Arqule Inc - ‍intends to use net proceeds from offering to advance clinical trials related to its proprietary pipeline​ (9-3)

CUSIP: 04269E107